Altogether, these findings document the cytostatic and cytotoxic effect of type I IFN (employed at concentrations that are detected in the circulation of AML patients) as secreted downstream of TLR3 activation on both AML malignant blasts and LSCs. This evidence concerns the gene TLR3 and acute myeloid leukemia.